{"id":5386,"date":"2025-12-11T02:42:21","date_gmt":"2025-12-11T02:42:21","guid":{"rendered":"https:\/\/regenerative-thermal-oxidizers.com\/?p=5386"},"modified":"2025-12-11T02:42:21","modified_gmt":"2025-12-11T02:42:21","slug":"rto-for-revolutionizing-tablet-capsule-fluid-bed-coating","status":"publish","type":"post","link":"https:\/\/regenerative-thermal-oxidizers.com\/zh\/rto-for-revolutionizing-tablet-capsule-fluid-bed-coating\/","title":{"rendered":"RTO For Revolutionizing Tablet\/Capsule Fluid Bed Coating"},"content":{"rendered":"
\n
\n

RTO For Revolutionizing Tablet\/Capsule Fluid Bed Coating<\/h1>\n

How our three-bed regenerative thermal oxidizer system efficiently handles high VOC loads from ethanol, isopropanol, and dichloromethane\u2014while maintaining LEL compliance and achieving >99% DRE in real-world pharmaceutical applications.<\/p>\n<\/div>\n

\n

When it comes to tablet or capsule fluid bed coating, you know the drill. Ethanol, isopropanol, and dichloromethane are your go-to solvents for uniform film formation. But here’s where things get tricky: those solvents off-gas during the process, creating a volatile cocktail of VOCs that need to be captured and destroyed. We’ve seen facilities struggle with peak concentrations ranging from 20\u2013100 g\/Nm\u00b3\u2014levels that can easily exceed 25% LEL if not properly managed. And let\u2019s not forget about the regulatory pressure. Under US EPA\u2019s NESHAP Subpart GG, emissions from coating operations must be controlled to meet stringent destruction removal efficiencies (DRE).<\/p>\n

The challenge isn\u2019t just about hitting DRE targets\u2014it\u2019s about doing so while managing concentration spikes and maintaining safety. Most standard RTO systems aren\u2019t equipped to handle these peaks without risking an explosion. The trick? Dilution air to keep everything below 25% LFL before entering the combustion chamber. In our experience, this approach not only ensures safety but also maximizes thermal efficiency by avoiding unnecessary fuel consumption.<\/p>\n

Understanding Your Process Emissions<\/h2>\n

Each step in the fluid bed coating process emits different compounds:<\/p>\n

\n\n\n\n\n\n\n\n
\u5de5\u827a\u6b65\u9aa4<\/th>\nKey VOC Components<\/th>\nTypical Flow & Concentration<\/th>\n\u72ec\u7279\u6311\u6218<\/th>\n<\/tr>\n<\/thead>\n
Initial Spray<\/td>\nEthanol, water vapor<\/td>\n50k\u2013100k Nm\u00b3\/h | 20\u201340 g\/Nm\u00b3<\/td>\nHigh humidity affects media performance<\/td>\n<\/tr>\n
Coating Application<\/td>\nIsopropanol, dichloromethane<\/td>\nVariable flow | peaks up to 100 g\/Nm\u00b3<\/td>\nSudden VOC spikes require rapid dilution<\/td>\n<\/tr>\n
Cooling Phase<\/td>\nLow VOC content<\/td>\nReduced airflow | low concentration<\/td>\nEnergy-efficient operation needed<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

Humidity plays a critical role too. During the initial spray phase, the exhaust stream contains significant amounts of water vapor mixed with ethanol. This moisture can degrade standard ceramic media over time, reducing heat retention and increasing fuel use. Our solution? Hydrophobic structured block media that repels water while maintaining high surface area for heat exchange.<\/p>\n

Navigating Regulatory Compliance Across Continents<\/h2>\n

Compliance isn’t one-size-fits-all. Pfizer Michigan has to adhere to strict US EPA guidelines, including a minimum DRE of 99% for all HAPs. Meanwhile, Novartis in Switzerland operates under TA-Luft regulations, which set limits on total organic carbon (TOC) emissions. In India, Sun Pharma follows CPCB norms, capping NMHC at 10 mg\/Nm\u00b3 for new installations. And then there’s China, where GB 31572-2015 mandates benzene levels below 1 mg\/Nm\u00b3\u2014a benchmark many plants struggle to meet consistently.<\/p>\n

We worked with a facility in Egypt where local regulations required biannual stack tests. Their previous system barely met standards, leading to constant anxiety about potential fines. By switching to our three-bed RTO with integrated LEL monitoring and dilution control, they achieved consistent compliance\u2014without sacrificing operational flexibility.<\/p>\n

Why Standard Two-Bed RTOs Fall Short in Pharmaceutical Applications<\/h2>\n

We\u2019ve seen numerous failures firsthand. Common issues?<\/p>\n